VIRACTA THERAPEUTICS

Viracta Therapeutics to Host R&D Day on October 4, 2023

05 Sep 2023 09:00:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Announces New Employment Inducement Grant

18 Aug 2023 16:05:03 By Nasdaq GlobeNewswire

Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

14 Aug 2023 08:00:01 By Nasdaq GlobeNewswire

Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma

08 Aug 2023 08:30:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

07 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Viracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)

28 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Viracta Therapeutics to Present at the Jefferies Healthcare Conference

31 May 2023 16:15:00 By Nasdaq GlobeNewswire

Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

11 May 2023 16:05:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates

08 May 2023 16:05:01 By Nasdaq GlobeNewswire

Viracta Therapeutics Announces Departure of Chief Medical Officer

02 May 2023 16:05:00 By Nasdaq GlobeNewswire

Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days

19 Apr 2023 16:30:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

13 Mar 2023 16:05:00 By Nasdaq GlobeNewswire

Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference

08 Mar 2023 16:05:00 By Nasdaq GlobeNewswire

Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference

07 Feb 2023 16:05:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma

19 Jan 2023 08:30:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives

08 Jan 2023 13:00:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress

30 Nov 2022 18:10:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Announces New Employment Inducement Grant

21 Nov 2022 17:08:25 By Nasdaq GlobeNewswire

Viracta Therapeutics Announces New Employment Inducement Grant

14 Nov 2022 16:42:22 By Nasdaq GlobeNewswire

Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs

10 Nov 2022 16:05:03 By Nasdaq GlobeNewswire